Key result
Modulation of the renin-angiotensin system with ACE inhibitors or ARBs may counteract SARS-CoV-2-related acute lung injury by restoring the balance between the classic and anti-RAS arms.
Why the study?
To review the evidence of renin-angiotensin system arm disequilibrium in COVID-19 and evaluate the hypothesis of a beneficial role for RAS modulation.
Does RAS modulation with ACE inhibitors or ARBs prevent or counteract acute lung injury in patients with COVID-19?
Does RAS modulation with ACE inhibitors or ARBs prevent or counteract acute lung injury in patients with COVID-19?
This review highlights the hypothesis that modulating the renin-angiotensin system with ACE inhibitors or ARBs may counteract acute lung injury in COVID-19 by restoring the balance between the classic and anti-RAS arms.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ACEi/ARB use in COVID-19 lung injury; randomized trials needed before practice change.
Sarzani et al. (2020) conducted a review in SARS-CoV-2-related lung injury. RAS modulation (ACE inhibitors and ARBs) was evaluated. Modulation of the renin-angiotensin system with ACE inhibitors or ARBs may counteract SARS-CoV-2-related acute lung injury by restoring the balance between the classic and anti-RAS arms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: